Generic Name and Formulations:
Nimodipine 3mg/mL; oral soln; contains ethanol.
Arbor Pharmaceuticals, LLC
Indications for NYMALIZE:
To improve neurological outcome by reducing the incidence and severity of ischemic deficits in adults with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of post-ictus neurological condition.
Start within 96hrs of subarachnoid hemorrhage. Take on empty stomach. Oral: 60mg (20mL) every 4hrs for 21 consecutive days. Via NG or gastric tube: use oral syringe; flush with 20mL normal saline after each dose. Cirrhosis: 30mg (10mL) every 4hrs; monitor.
Not for IV or other parenteral administration. Monitor BP and heart rate during treatment (esp. patients w. cirrhosis). Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate effects of anti-hypertensives (eg, diuretics, beta-blockers, ACEIs, ARBs, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, α-methyldopa; monitor and adjust dose if needed. Increased risk of hypotension with concomitant strong CYP3A4 inhibitors (eg, clarithromycin, telithromycin, indinavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir, ketoconazole, itraconazole, posaconazole, voriconazole, conivaptan, delaviridine, nefazodone): avoid. May be potentiated by moderate and weak CYP3A4 inhibitors (eg, alprazolam, amprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinupristin/dalfopristin, valproic acid, verapamil); monitor and reduce nimodipine dose may be needed. Avoid concomitant grapefruit juice. Antagonized by concomitant strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. Johns wort): avoid. May be antagonized by moderate and weak CYP3A4 inducers (eg, amprenavir, aprepitant, armodafinil, bosentan, efavirenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib); monitor and increase nimodipine dose may be needed.
Calcium channel blocker (CCB).
Hypotension, headache, nausea, bradycardia.
Soln—473mL; Unit-dose cups (10mL, 20mL)—12 (w. oral syringes)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Researchers Identify Novel Potential Biomarkers for Autism
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users